Posted by Michael Wonder on 17 Mar 2017
NICE publishes draft guidance on the use of daratumumab (Darzalex) on the NHS
17 March 2017 - The Department of Health has asked NICE to produce guidance on the use of daratumumab as monotherapy in the NHS in England.
Daratumumab monotherapy is not recommended, within its marketing authorisation, for treating relapsed and refractory multiple myeloma in adults, that is, after therapy including a proteasome inhibitor and an immunomodulatory agent and whose disease has progressed on the last therapy.
The use of daratumumab on the NHS will be considered at a second appraisal committee meeting on 20 April 2017.
